

February 24, 2022

To whom it may concern

Announcement of Winning the Case of Eldecalcitol Patent Litigation and Other Proceedings

In connection with the production and use of raw materials for the production and sales of generic medicine of Eldecalcitol, Nissan Chemical Corporation (Head Office: Chuo-ku, Tokyo; President: YAGI Shinsuke) received a patent infringement lawsuit (Patent Number: JP3429432) and petitions for provisional disposition orders by Chugai Pharmaceutical Co. Ltd., (hereinafter referred to as “Chugai Pharmaceutical”), all of which were dated February 17, 2021 and filed to the Tokyo District Court. Since then, we have been taking actions therefor.

We today announce that the Tokyo District Court has dismissed Chugai Pharmaceutical’s complaints on February 24, 2022.

1. About Eldecalcitol

An active ingredient of osteoporosis medication (active form of vitamin D3) Eldecalcitol Capsules

2. Our Outlook

At this point, no effect is expected on Nissan Chemical Corporation’s business.

Under our corporate philosophy “Contribute to society in harmony with the environment based on our excellent technologies, products, and services,” we believe that it is utmost important to secure and appropriately execute intellectual property rights. Based on this belief, we will continue our business while giving respect to others’ rights.

Contact for further information
CSR & Public Relations Office, Corporate Planning Department, Nissan Chemical Co., Ltd. (Nihonbashi Takashimaya Mitsui Building, 2-5-1 Nihonbashi, Chuo-ku, Tokyo) TEL:03-4463-8123 E-mail: csr_pr@nissanchem.co.jp